Analyst Price Targets — AXS
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| July 15, 2026 3:46 pm | — | Atlantic Equities | $122.00 | $111.55 | TheFly | Axis Capital price target raised to $122 from $115 at BofA |
| July 9, 2026 11:17 am | — | Mizuho Securities | $142.00 | $112.85 | TheFly | Axis Capital price target raised to $142 from $137 at Mizuho |
| July 8, 2026 12:45 pm | Brian Meredith | UBS | $131.00 | $114.00 | TheFly | Axis Capital price target raised to $131 from $129 at UBS |
| May 4, 2026 11:44 am | — | Mizuho Securities | $137.00 | $100.13 | TheFly | Axis Capital price target lowered to $137 from $140 at Mizuho |
| April 13, 2026 3:00 pm | — | Mizuho Securities | $140.00 | $99.23 | TheFly | Axis Capital price target lowered to $140 from $141 at Mizuho |
| February 2, 2026 12:23 pm | — | Mizuho Securities | $141.00 | $103.18 | TheFly | Axis Capital price target raised to $141 from $133 at Mizuho |
| February 2, 2026 11:26 am | Brian Meredith | UBS | $129.00 | $103.18 | TheFly | Axis Capital price target raised to $129 from $126 at UBS |
| January 30, 2026 2:26 pm | — | UBS | $130.00 | $104.12 | TheFly | Axis Capital price target raised to $130 from $125 at RBC Capital |
| January 30, 2026 2:03 pm | — | Jefferies | $122.00 | $103.51 | TheFly | Axis Capital price target raised to $122 from $121 at Jefferies |
| January 29, 2026 1:59 pm | — | Roth Capital | $120.00 | $103.92 | TheFly | Axis Capital price target raised to $120 from $110 at Roth Capital |
Latest News for AXS
Axis Capital (AXS) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
AXSM advances AXS-12 toward potential approval after the FDA accepts its NDA for cataplexy in narcolepsy and sets a May 2027 decision date.
FDA sets PDUFA target action date of May 1, 2027 NEW YORK, July 15, 2026 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today announced that the U.S. Food and Drug Administration (FDA) has accepted for filing the Company's New Drug Application (NDA) for AXS-12 (reboxetine) for the treatment of…
PEMBROKE, Bermuda, July 06, 2026 (GLOBE NEWSWIRE) -- AXIS Capital Holdings Limited (“AXIS Capital” or the “Company”) (NYSE: AXS) today announced that it expects to release financial results for the second quarter ended June 30, 2026 on Tuesday, July 28, 2026 after the close of the financial markets. Vince Tizzio, President and Chief Executive Officer, and Matthew Kirk, Chief Financial Officer, will host an investor…
Axis Capital (AXS) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
Senate Trading Disclosures
| Name | Transaction Date | Type | Asset | Amount | Link |
|---|
U.S. House Trading
House Trades Disclosures
| Name | Transaction Date | Type | Asset | Amount | Link |
|---|
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.